Key result
Dual-targeted hypolipidemic therapy lowers refractory lipids in combined familial hypercholesterolemia and sitosterolemia.
Case Report (n=1)
This first reported case of concurrent FH and sitosterolemia highlights the value of genetic testing to guide precise combined hypolipidemic treatment in refractory hyperlipidemia.
BACKGROUND: Hyperlipidemia is a heterogeneous disorder with genetic and acquired causes, and severe forms may cause vascular calcification and stenosis. Familial hypercholesterolemia (FH) and sitosterolemia are distinct inherited lipid diseases, yet their co-occurrence has not been previously reported. CASE SUMMARY: A patient with combined FH and sitosterolemia was identified via genetic testing. Single hypolipidemic therapies failed, whereas combined treatment targeting both disorders achieved significant lipid reduction. DISCUSSION: This is to our knowledge the first reported case of concurrent FH and sitosterolemia, expanding the spectrum of inherited hyperlipidemia and highlighting the value of targeted therapy for dual lipid metabolic disorders. TAKE-HOME MESSAGE: Genetic testing is indispensable for patients with refractory hyperlipidemia to guide precise combined hypolipidemic treatment.
No takes yet. Share an insight, caveat, or question.
Sun et al. (2026) conducted a case report in Familial Hypercholesterolemia Combined With Sitosterolemia (n=1). Combined hypolipidemic treatment vs. Single hypolipidemic therapies was evaluated on Lipid reduction. Combined hypolipidemic treatment targeting both familial hypercholesterolemia and sitosterolemia achieved significant lipid reduction after single therapies failed.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: